TrxR-IN-3 is a potent thioredoxin reductase (TrxR) inhibitor with significant antiproliferative activity against five human cancer cell lines, particularly breast tumor cells; it induces apoptosis by upregulating ROS levels and modulating apoptosis-related proteins in breast cancer cells; additionally, it triggers autophagosome and autolysosome formation by promoting the expression of LC3-II and Beclin-1 while downregulating LC3-I and p62 protein levels.